Zhimeng Biopharma Advances ALS Treatment with CB03-154 in Clinical Trial Phase Zhimeng Biopharma's CB03-154 for ALS has reached a major milestone in its clinical trial, signaling hope for new treatment options for this severe disease.

Zhimeng Biopharma Advances ALS Treatment with CB03-154 in Clinical Trial Phase #China #Shanghai #ALS_Treatment #Zhimeng_Biopharma #CB03-154

Zhimeng Biopharma's Breakthrough Drug CB03-154 Approved for Phase 2 Trial in China Zhimeng Biopharma's novel drug, CB03-154, has been approved for a Phase 2 clinical trial for refractory epilepsy in China, aiming to address unmet medical needs.

Zhimeng Biopharma's Breakthrough Drug CB03-154 Approved for Phase 2 Trial in China #China #Shanghai #Epilepsy #Zhimeng_Biopharma #CB03-154

Zhimeng Biopharma's Breakthrough ALS Drug Moves to Clinical Trials in China Zhimeng Biopharma's new KCNQ2/3 potassium channel opener, CB03-154, has been approved for Phase 2/3 ALS trials in China, offering hope for patients.

Zhimeng Biopharma's Breakthrough ALS Drug Moves to Clinical Trials in China #China #Shanghai #ALS #Zhimeng_Biopharma #CB03-154